Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 3/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241363 | 0.78 | PDPK1 (0.42) | KDM4ECYP3A4TP53CDK2FGFR1 | |
| SCHEMBL4447459 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1RXFP1TP53CDK2 | |
| SCHEMBL31058752 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1RXFP1TP53CDK2 | |
| SCHEMBL3578267 | 0.72 | ALDH1A1 (0.53) | KDM4EALDH1A1RXFP1TP53CDK2 | |
| SCHEMBL3044447 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1RXFP1HPRT1CDK2 | |
| SCHEMBL3054589 | 0.71 | ALDH1A1 (0.40) | KDM4EALDH1A1RXFP1TYMPHPRT1 | |
| SCHEMBL9617743 | 0.71 | ALDH1A1 (0.40) | KDM4EALDH1A1RXFP1HPRT1CDK2 | |
| SCHEMBL4241346 | 0.70 | CYP3A4 (0.38) | TYMPHPRT1CYP3A4FGFR1SLC22A6 | |
| SCHEMBL8708640 | 0.69 | ALDH1A1 (0.38) | KDM4EALDH1A1RXFP1HPRT1CDK2 | |
| SCHEMBL2640836 | 0.68 | ALDH1A1 (0.53) | KDM4EALDH1A1RXFP1CDK2MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1933848-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | Innate Pharma (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | KDM4E 4391/4885ALDH1A1 4878/4885RXFP1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.